15 completed, 8 active not recruiting, 6 terminated, 1 recruiting. 31 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 31 | Completed 15, Active not recruiting 8, Terminated 6, Recruiting 1, Withdrawn 1 |
| Phase 1 | 5 | Completed 3, Recruiting 1, Terminated 1 |
Follow adavosertib: new trials by email Literature Review of adavosertib trials Research Report on adavosertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adavosertib and Gemcitabine in Advanced Pancreatic Adavosertib, Gemcitabine - Pancreatic Cancer | Phase 2 | Withdrawn | James Cleary, MD, PhD | 2022-06-01 | 2022-06-14 | |
| A Study of Adavosertib as Treatment for Uterine Serous Carcinoma Adavosertib - Uterine Serous Carcinoma | Phase 2 | Completed | AstraZeneca | 109 | 2020-11-30 | 2023-08-14 |
| Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 Adavosertib - Clear Cell Renal Cell Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 18 | 2019-01-29 | 2026-10-23 |
| AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification Adavosertib - Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm | Phase 2 | Completed | National Cancer Institute (NCI) | 31 | 2019-01-16 | 2023-10-17 |
| Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Adavosertib, Olaparib, Ceralasertib - Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 96 | 2018-12-07 | 2026-07-16 |
| AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma AZD1775 - Uterine Cancer | Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 49 | 2018-10-22 | 2026-09-28 |
| Prostate Cancer Biomarker Enrichment and Treatment Selection Adavosertib, Savolitinib, Darolutamide - Prostate Cancer | Phase 2 | Active not recruiting | Canadian Cancer Trials Group | 200 | 2018-08-01 | 2025-08-21 |
| To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy. Olaparib Continuous (28-Day cycle) 300 mg BD., Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle)., Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle). - Metastatic Triple Negative Breast Cancer | Phase 2 | Active not recruiting | AstraZeneca | 273 | 2018-03-07 | 2026-10-14 |
| WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome Cytarabine, Laboratory Biomarker Analysis, Pharmacological Study - Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Isolated Del(5q) | Phase 2 | Completed | Mayo Clinic | 3 | 2017-05-05 | 2019-09-06 |
| Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I) Adavosertib - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 33 | 2017-03-24 | 2026-11-18 |
| CISPLATIN + AZD-1775 In Breast Cancer Cisplatin, AZD1775 - Triple-negative Metastatic Breast Cancer | Phase 2 | Completed | Dana-Farber Cancer Institute | 34 | 2017-01-18 | 2021-11-23 |
| A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer Durvalumab and Tremelimumab, AZD1775 and carboplatin (CBPT), AZD6738 and olaparib - Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma | Phase 2 | Completed | AstraZeneca | 72 | 2016-11-28 | 2024-06-07 |
| European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors Ribociclib, Topotecan, Temozolomide - Pediatric Cancer | Phase 1 / Phase 2 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 472 | 2016-08-03 | 2026-07-10 |
| Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation AZD1775 - Small Cell Lung Cancer | Phase 2 | Terminated | Samsung Medical Center | 7 | 2016-06-07 | 2018-09-20 |
| Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients AZD1775 - Small Cell Lung Cancer | Phase 2 | Completed | Samsung Medical Center | 24 | 2015-12-01 | 2021-03-19 |
| OLAParib COmbinations AZD2281, AZD5363, AZD1775 - Cancer | Phase 2 | Terminated | Joseph Paul Eder | 67 | 2015-11-01 | 2022-12-28 |
| AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer Carboplatin, Paclitaxel, AZD1775 - Lung Cancer | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 42 | 2015-10-13 | 2026-02-19 |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Adavosertib, Afatinib, Afatinib Dimaleate - Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 6452 | 2015-08-17 | 2026-11-12 |
| Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Adavosertib, Paclitaxel, Carboplatin - Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation | Phase 2 | Completed | AstraZeneca | 95 | 2015-01-30 | 2023-10-03 |
| Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy AZD1775, paclitaxel - Advanced Gastric Adenocarcinoma | Phase 2 | Completed | Samsung Medical Center | 26 | 2015-01-14 | 2022-06-15 |
Showing 20 of 31. Sign in to see all of them.
Ovarian Neoplasms (4) · Lung Neoplasms (3) · Neoplasms (3) · Carcinoma, Renal Cell (2) · Fallopian Tube Neoplasms (2) · Hematologic Neoplasms (2) · Lymphoma (2) · Multiple Myeloma (2) · Pancreatic Neoplasms (2) · Prostatic Neoplasms (2) · Small Cell Lung Carcinoma (2) · Uterine Cervical Neoplasms (2) · Uterine Neoplasms (2) · Breast Neoplasms (1) · Brenner Tumor (1)
National Cancer Institute (NCI) (9) · AstraZeneca (6) · Samsung Medical Center (3) · Dana-Farber Cancer Institute (2) · Merck Sharp & Dohme LLC (2) · Canadian Cancer Trials Group (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · James Cleary, MD, PhD (1) · Joseph Paul Eder (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · The Netherlands Cancer Institute (1) · University of Michigan Rogel Cancer Center (1)
United States (20) · Canada (7) · Netherlands (4) · South Korea (4) · Spain (4) · France (3) · Italy (3) · Germany (2) · Poland (2) · United Kingdom (2) · Belgium (1) · Czechia (1) · Denmark (1) · Guam (1) · Hungary (1)
David R Spigel, MD (2) · A P Chen (1) · Aaron Hansen (1) · Amit M Oza (1) · Andrew Tutt, MB ChB PhD (1) · Birgit Geoerger, MD (1) · Eric Winquist (1) · FL Opdam, MD PhD (1) · Haiyi Jiang, M.D. (1) · James Cleary, MD, PhD (1) · Jennifer R Eads (1) · Jhanelle Gray, M.D. (1) · Joseph P Eder, MD (1)
PMID 41212474, PMID 26586415, PMID 26602013, PMID 27998224, PMID 31398082, PMID 31538815, PMID 32203306, PMID 32463741, PMID 33048619, PMID 33485453, PMID 33705205, PMID 33892407, PMID 34347542, PMID 34543871, PMID 34645648, PMID 34716177, PMID 34904813, PMID 35133871, PMID 35138919, PMID 35292802, PMID 36351402, PMID 36469840, PMID 37053535, PMID 37236033, PMID 37322121, PMID 37934000, PMID 38591867, PMID 38920407, PMID 39666929, PMID 39693587, PMID 39913886, PMID 40262070, PMID 40865033, PMID 41066729, PMID 41838385, PMID 42686334
U10CA180820 (3), 2016 (2), N01CM00032 (2), U24CA196172 (2), 2009 (1), 2015 (1), 2017 (1), N01CM00038 (1), N01CM00071 (1), P30CA015083 (1), U10CA021115 (1), U10CA180821 (1), UM1CA097452 (1), UM1CA186644 (1), UM1CA186688 (1)